Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention.

• Urban P La Tour Hospital, Geneva, Switzerland (P.U.).
• Mehran R Icahn School of Medicine at Mount Sinai, New York, NY (R.M.).
• Colleran R Deutsches Herzzentrum München, Technische Universität München, Germany (R.C., R.A.B.).
• Angiolillo DJ Division of Cardiology, University of Florida College of Medicine, Jacksonville (D.J.A.).
• Byrne RA Deutsches Herzzentrum München, Technische Universität München, Munich, Germany (R.A.B.).
• Capodanno D Cardio-Thoracic-Vascular Department, Centro Alte Specialità e Trapianti (D. Capodanno), Catania, Italy.
• Cuisset T Département de Cardiologie, Centre Hospitalier Universitaire Timone and Inserm, Inra, Centre de recherche en cardiovasculaire et nutrition, Faculté de Médecine, Aix-Marseille Université, Marseille, France (T.C.).
• Cutlip D Cardiology Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA (D. Cutlip).
• Eerdmans P Head of the Notified Body, DEKRA Certification B.V. (P.E.).
• Eikelboom J Department of Medicine, McMaster University, Hamilton, Canada (J.E.).
• Farb A US Food and Drug Administration, Silver Spring, MD (A.F., J.L., P.F.A.M., N.S.).
• Gibson CM Baim Institute for Clinical Research, Brookline, MA (C.M.G.).
• Gregson J London School of Hygiene and Tropical Medicine, UK (J.G., S.P.).
• Haude M Städtische Kliniken Neuss, Lukaskrankenhaus GmbH, Germany (M.H.).
• James SK Department of Medical Sciences and Uppsala Clinical Research Center, Uppsala University, Sweden (S.K.J.).
• Kim HS Cardiovascular Center, Seoul National University Hospital, Korea (H.-S.K.).
• Kimura T Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Japan (T.K.).
• Konishi A Office of Medical Devices 1, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan (A.K., Y.M.).
• Laschinger J US Food and Drug Administration, Silver Spring, MD (A.F., J.L., P.F.A.M., N.S.).
• Leon MB Columbia University Medical Center, New York, NY (M.B.L.).
• Magee PFA US Food and Drug Administration, Silver Spring, MD (A.F., J.L., P.F.A.M., N.S.).
• Mitsutake Y Office of Medical Devices 1, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan (A.K., Y.M.).
• Mylotte D University Hospital and National University of Ireland, Galway (D.M.).
• Pocock S London School of Hygiene and Tropical Medicine, UK (J.G., S.P.).
• Price MJ Scripps Clinic, La Jolla, CA (M.J.P.).
• Rao SV Duke Clinical Research Institute, Durham, NC (S.V.R., M.W.K.).
• Spitzer E Thoraxcenter, Erasmus University Medical Center, Rotterdam, the Netherlands (E.S.).
• Stockbridge N US Food and Drug Administration, Silver Spring, MD (A.F., J.L., P.F.A.M., N.S.).
• Valgimigli M Department of Cardiology, Inselspital, University of Bern, Switzerland (M.V.).
• Varenne O Service de Cardiologie, Hôpital Cochin, Assistance publique - hôpitaux de Paris, Paris, France (O.V.).
• Windhoevel U Cardiovascular European Research Center, Massy, France (P.U., U.W., M.-C.M.).
• Yeh RW Beth Israel Deaconess Medical Center, Boston, MA (R.W.Y.).
• Krucoff MW Duke Clinical Research Institute, Durham, NC (S.V.R., M.W.K.).
• Morice MC Cardiovascular European Research Center, Massy, France (P.U., U.W., M.-C.M.).

Show more…

clinical trial protocols as topic

hemorrhage

percutaneous coronary intervention

Anticoagulants

Congresses as Topic

Consensus

District of Columbia

Hemorrhage

Humans

Paris

Percutaneous Coronary Intervention

Risk Assessment